P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib-Reference-Cited by-同舟云学术

P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib

Published:2021-11-03 Issue:12 Volume:18 Page:4371-4384
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

F. Martins Margarida L.¹^ORCID,Loos Nancy H. C.¹,Mucuk Sümeyra¹,de Jong Danielle²,Lebre Maria C.¹,Rosing Hilde²,Tibben Matthijs²,Beijnen Jos H.¹²³,Schinkel Alfred H.¹^ORCID

Affiliation:

1. Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

2. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

3. Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands

Funder

Di-AcetylM BV

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.1c00553

Reference64 articles.

1. Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors

2. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer

3. PARP inhibitors: Synthetic lethality in the clinic

4. FDA. Tesaro. ZEJULA (Niraparib): US Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf (accessed Apr 8, 2021).

5. EMA. Tesaro. ZEJULA (Niraparib): EU Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/zejula-epar-product-information_en.pdf (accessed Apr 8, 2021).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20

2. PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database;Expert Opinion on Drug Safety;2024-07-08

3. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03

4. Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics;Expert Opinion on Pharmacotherapy;2023-12-12

5. Predictability of human exposure by human‐CYP3A4‐transgenic mouse models: A meta‐analysis;Clinical and Translational Science;2023-12